Top

Breast Cancer Research and Treatment

Published in:

01-11-2018 | Epidemiology

Screening status, tumour subtype, and breast cancer survival: a national population-based analysis

Authors: Katie M. O’Brien, Therese Mooney, Patricia Fitzpatrick, Linda Sharp

Published in: Breast Cancer Research and Treatment | Issue 1/2018

Abstract

Purpose

We examined whether demographic and tumour characteristics (including subtype) were different for women with breast cancer diagnosed via mammography screening compared with women with interval breast cancers, lapsed attenders of the screening programme and non-participants of the screening programme. In addition, we explored whether there were survival differences between the groups, taking into account lead time bias.

Methods

We used linked data from National Cancer Registry Ireland and the national breast screening programme BreastCheck. Multinomial logistic regression was used to test the association of covariates with screening status. For survival analysis, we corrected the survival time for screen-detected cases for lead time bias, examined Kaplan–Meier curves and then used Cox regression to investigate differences in survival by screening status.

Results

Subtype (HER2 over-expressing, triple negative), stage (III/IV), grade (poor), having co-morbidities, area of deprivation, smoking status and age were associated with having interval cancer or being a non-participant of the screening programme in the multivariable model. After correcting for lead time bias, and adjusting for variables associated with screening status, there was no evidence that risk of breast-cancer death for women with screen-detected cancer was different from women with interval cancer (HR = 0.76, 95% CI 0.56–1.03), non-participants (HR = 1.07, 95% CI 0.84–1.37) and lapsed attenders (HR = 0.97, 95% CI 0.65–1.45).

Conclusions

Screening status was strongly associated with subtype and this association persisted after adjustment for covariates including tumour stage and grade. After correcting for lead-time bias and adjusting for stage, subtype, grade and socio-demographic variables, no significant survival difference was demonstrated for women with screen-detected cancer in the 5-year period post-diagnosis. Since we are adjusting for stage, subtype and other variables, the lack of difference between these groups would be expected but has not been demonstrated in studies which do not correct for lead time bias.

Available only for authorised users

Bleyer A, Baines C, Miller AB (2016) Impact of screening mammography on breast cancer mortality. Int J Cancer 138(8):2003–2012CrossRef

Nyström L, Bjurstam N, Jonsson H, Zackrisson S, Frisell J (2016) Reduced breast cancer mortality after 20+ years of follow-up in the Swedish randomized controlled mammography trials in Malmö, Stockholm, and Göteborg. J Med Screen 24(1):34–42CrossRef

Weedon-Fekjær H, Romundstad PR, Vatten LJ (2014) Modern mammography screening and breast cancer mortality: population study. BMJ 348:g3701CrossRef

Independent UK Panel on Breast Cancer Screening (2012) The benefits and harms of breast cancer screening: an independent review. Lancet 380(9855):1778–1786CrossRef

Hanley JA, Hannigan A, O’Brien KM (2017) Mortality reductions due to mammography screening: contemporary population-based data. PLoS ONE 12(12):e0188947CrossRef

Gøtzsche PC, Jørgensen KJ (2013) Screening for breast cancer with mammography. Cochrane Database Syst Rev (6):CD001877

Myers ER, Moorman P, Gierisch JM, Havrilesky LJ, Grimm LJ, Ghate S et al (2015). Benefits and harms of breast cancer screening: a systematic review. JAMA 314(15):1615–1634CrossRef

Rothman KJ (2012) Epidemiology: an introduction, 2nd edn. Oxford University Press, Oxford

Onitilo AA, Engel JM, Greenlee RT, Mukesh BN (2009) Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 7(1–2):4–13CrossRef

10.

Ihemelandu CU, Leffall LD, Dewitty RL, Naab TJ, Mezghebe HM, Makambi KH et al (2007) Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival. J Surg Res 143(1):109–118CrossRef

11.

Hofvind S, Holen Å, Román M, Sebuødegård S, Puig-Vives M, Akslen L (2016) Mode of detection: an independent prognostic factor for women with breast cancer. J Med Screen 23(2):89–97CrossRef

12.

Baré M, Torà N, Salas D, Sentís M, Ferrer J, Ibáñez J et al (2015) Mammographic and clinical characteristics of different phenotypes of screen-detected and interval breast cancers in a nationwide screening program. Breast Cancer Res Treat 154(2):403–415CrossRef

13.

Boyd NF, Huszti E, Melnichouk O, Martin LJ, Hislop G, Chiarelli A et al (2014) Mammographic features associated with interval breast cancers in screening programs. Breast Cancer Res 16:417CrossRef

14.

O’Brien KM, Dwane F, Kelleher T, Sharp L, Comber H (2015) Interval cancer rates in the Irish national breast screening programme. J Med Screen 22(3):136–143CrossRef

15.

Törnberg S, Codd M, Rodrigues V, Segnan N, Ponti A (2005) Ascertainment and evaluation of interval cancers in population-based mammography screening programmes: a collaborative study in four European centres. J Med Screen 12(1):43–49CrossRef

16.

de Camargo Cancela M, Comber H, Sharp L (2015) Which women with breast cancer do, and do not, undergo receptor status testing? A population-based study. Cancer Epidemiol N Y 39(5):778–782CrossRef

17.

Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn H-J (2011) Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22(8):1736–1747CrossRef

18.

Wiley MM (2005) Using HIPE data as a research and planning tool: limitations and opportunities: a response. Ir J Med Sci 174(2):52–57CrossRef

19.

Black R, Brewster D, Brown H, Fraser L, Harris V, Kidd J et al (2000) Trends in cancer survival in Scotland 1971–1995. ISD NHS in Scotland, Edinburgh (Scottish Cancer Intelligence Unit)

20.

Walsh PM, Byrne J, Kelly M, McDevitt J, Comber H (2014) Socioeconomic disparity in survival after breast cancer in Ireland: observational study. PLoS ONE 9(11):e111729CrossRef

21.

Small Area Health Research Unit (SAHRU) (1997) A National Deprivation Index for health and health services research. Technical Report No. 2. Dublin. http://hdl.handle.net/10147/264013

22.

Kruskal WH, Wallis WA (1952) Use of ranks in one-criterion variance analysis. J Am Stat Assoc 47(260):583–621CrossRef

23.

Allgood PC, Duffy SW, Kearins O, O’Sullivan E, Tappenden N, Wallis MG et al (2011) Explaining the difference in prognosis between screen-detected and symptomatic breast cancers. Br J Cancer 104(11):1680–1685CrossRef

24.

Tabár L, Vitak B, Chen HH, Duffy SW, Yen MF, Chiang CF et al (2000) The Swedish Two-County Trial twenty years later. Updated mortality results and new insights from long-term follow-up. Radiol Clin N Am 38(4):625–651CrossRef

25.

Bellio G, Marion R, Giudici F, Kus S, Tonutti M, Zanconati F et al (2017) Interval breast cancer versus screen-detected cancer: comparison of clinicopathologic characteristics in a single-center analysis. Clin Breast Cancer 17(7):564–571CrossRef

26.

Kim J, Lee S, Bae S, Choi M-Y, Lee J, Jung SP et al (2012) Comparison between screen-detected and symptomatic breast cancers according to molecular subtypes. Breast Cancer Res Treat 131(2):527–540CrossRef

27.

Pollán M, Ascunce N, Ederra M, Murillo A, Erdozáin N, Alés-Martínez J et al (2013) Mammographic density and risk of breast cancer according to tumor characteristics and mode of detection: a Spanish population-based case-control study. Breast Cancer Res (BCR) 15(1):R9CrossRef

28.

Aro AR, de Koning HJ, Absetz P, Schreck M (2001) Two distinct groups of non-attenders in an organized mammography screening program. Breast Cancer Res Treat 70(2):145–153CrossRef

29.

Aro AR, de Koning HJ, Absetz P, Schreck M (1999) Psychosocial predictors of first attendance for organised mammography screening. J Med Screen 6(2):82–88CrossRef

30.

Coyle C, Kinnear H, Rosato M, Mairs A, Hall C, O’Reilly D (2014) Do women who intermittently attend breast screening differ from those who attend every invitation and those who never attend? J Med Screen 21(2):98–103CrossRef

Title: Screening status, tumour subtype, and breast cancer survival: a national population-based analysis
Authors: Katie M. O’Brien
Therese Mooney
Patricia Fitzpatrick
Linda Sharp
Publication date: 01-11-2018
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2018
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-018-4877-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2018

Clinical subtypes and prognosis of pregnancy-associated breast cancer: results from the Korean Breast Cancer Society Registry database

Impact of race, ethnicity, and socioeconomic factors on receipt of radiation after breast conservation surgery: analysis of the national cancer database

Population-based validation of the National Cancer Comprehensive Network recommendations for breast cancer staging

The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer

Intra-tumor molecular heterogeneity in breast cancer: definitions of measures and association with distant recurrence-free survival

Molecular subtypes of screen-detected breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer